GSK(US:GSK) Bei Ke Cai Jing·2026-01-23 11:49Core Viewpoint - GSK has received approval from the National Medical Products Administration for the new indication of its inhalation powder, Trelegy (FF/UMEC/VI), for maintenance treatment in adult asthma patients, expanding its previous indication for chronic obstructive pulmonary disease (COPD) [1][2]. Group 1: Product Information - Trelegy is now the first and only single-inhaler triple therapy in China for both asthma and COPD maintenance treatment [1]. - The inhalation powder is administered once daily through a single inhalation device and contains three components: inhaled corticosteroid (ICS) fluticasone furoate (FF), long-acting muscarinic antagonist (LAMA) umeclidinium (UMEC), and long-acting β2-adrenergic agonist (LABA) vilanterol (VI) [1]. Group 2: Market Context - Asthma is one of the most common chronic respiratory diseases, with about half of the patients not achieving effective symptom control, which increases the risk of acute attacks and affects quality of life [2]. - The approval of the new indication provides an important treatment option for adult asthma patients who are not optimally controlled and face the risk of acute exacerbations [2].